Hikma Pharmaceuticals
UK-headquartered pharmaceutical company
HIK London SE
ISIN GB00B0LCW083 LEI 549300BNS685UXH4JI75
Follow Hikma Pharmaceuticals
Weekly email: filings, results
Revenue, last year
$3.3B
+7.1% vs prior year
Net income
$402M
+12% vs prior year
EPS, diluted
$1.81
+12.4% vs prior year
Operating cash flow
$436M
−22.7% vs prior year
Source: ESEF annual reports · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $3.3B | $402M |
| FY24 | $3.1B | $359M |
| FY23 | $2.9B | $190M |
| FY22 | $2.5B | $188M |
| FY21 | $2.6B | $421M |
| FY20 | $2.3B | $431M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 43% | 16.2% | 12% |
| FY24 | 45.3% | 19.6% | 11.5% |
| FY23 | 48.3% | 12.8% | 6.6% |
| FY22 | 49.2% | 11.2% | 7.5% |
| FY21 | 51% | 22.8% | 16.5% |
| FY20 | 51.3% | 24.7% | 18.4% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $239M |
| FY24 | $399M |
| FY23 | $439M |
| FY22 | $392M |
| FY21 | $493M |
| FY20 | $292M |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | $185M | $36M |
| FY24 | $175M | $38M |
| FY23 | $137M | $0 |
| FY22 | $125M | $300M |
| FY21 | $120M | $0 |
| FY20 | $109M | $375M |
- Hikma Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Hikma Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | 12% | −30.6% |
| FY24 | 11.5% | −47% |
| FY23 | 6.6% | −58% |
| FY22 | 7.5% | −80.4% |
| FY21 | 16.5% | −71.9% |
| FY20 | 18.4% | −62.2% |